Compare SCYX & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCYX | COCH |
|---|---|---|
| Founded | 1999 | 1995 |
| Country | United States | United States |
| Employees | 29 | 47 |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.4M | 49.7M |
| IPO Year | 2014 | N/A |
| Metric | SCYX | COCH |
|---|---|---|
| Price | $0.71 | $0.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.00 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 338.4K | 117.8K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $257,000.00 | N/A |
| Revenue This Year | N/A | $1.58 |
| Revenue Next Year | $608.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $0.36 |
| 52 Week High | $1.29 | $1.89 |
| Indicator | SCYX | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 32.56 | 57.34 |
| Support Level | $0.59 | $0.63 |
| Resistance Level | $0.70 | $0.73 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 16.89 | 69.89 |
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.